5-(4-氨基苯基)-2-甲基呋喃-3-羧酸乙酯 | 175276-70-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃
• 中文名称: 5-(4-氨基苯基)-2-甲基呋喃-3-羧酸乙酯
• 英文名称: ethyl 5-(4-aminophenyl)-2-methyl-3-furanecarboxylate
• 英文别名: Ethyl 5-(4-Aminophenyl)-2-Methyl-3-Furoate；ethyl 5-(4-aminophenyl)-2-methylfuran-3-carboxylate
• CAS: 175276-70-7
• 化学式: C₁₄H₁₅NO₃
• 分子量: 245.278
• InChiKey: HOOXMKJYQNXIIY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  65.5
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2932190090

SDS

Name:	Ethyl 5-(4-aminophenyl)-2-methyl-3-furoate 97% Material Safety Data Sheet
Synonym:
CAS:	175276-70-7

Section 1 - Chemical Product MSDS Name:Ethyl 5-(4-aminophenyl)-2-methyl-3-furoate 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
175276-70-7	Ethyl 5-(4-aminophenyl)-2-methyl-3-fur	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 175276-70-7: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: brown
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 58 - 61 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C14H15NO3
Molecular Weight: 245

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, bases, acid chlorides, halogenated agents, halogens.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 175276-70-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Ethyl 5-(4-aminophenyl)-2-methyl-3-furoate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 175276-70-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 175276-70-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 175276-70-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-(4-氨基苯基)-2-甲基呋喃-3-羧酸乙酯 在 硫酸 、 水 、 sodium nitrite 作用下， 反应 1.42h， 以20%的产率得到ethyl 5-(4-hydroxyphenyl)-2-methyl-3-furanecarboxylate
  参考文献：
  名称：

  Non-nucleoside reverse transcriptase inhibitors

  摘要：

  通过式I表示的化合物：其中R2从H、(C1-4)烷基、卤素、卤代烷基、OH、(C1-6)烷氧基、NH(C1-4烷基)或N(C1-4烷基)2的组中选择；R4为H或Me；R5为H或Me；R11为H、(C1-4)烷基、(C3-4)环烷基和(C1-4)烷基-(C3-4)环烷基；A为(C1-3)烷基的连接链；B为O或S；n为0或1；其中当n为0时：环C为具有1至4个来自O、N和S的杂原子的6-或10-成员芳基或5-或6-成员杂环，所述芳基和所述杂环可选地被取代；E为CONR12R13；CONHNR14R15；NR16COR17；NR18SO2(C1-6)烷基；SO2NR19R20；或SO2R21；或当n为1时：环C如上定义，E为单键或连接基；和环D为具有1至4个来自O、N和S的杂原子的6-或10-成员芳基或5-或6-成员杂环，所述芳基和所述杂环可选地被1至5个取代基取代；或其盐或前药作为HIV逆转录酶的抑制剂。

  公开号：

  US20040006071A1
• 作为产物：
  描述：

  2-甲基-5-(4-硝基苯基)呋喃-3-羧酸乙酯 在 盐酸 、 铁粉 作用下， 以 乙醇 、 水 为溶剂， 反应 2.0h， 以89%的产率得到5-(4-氨基苯基)-2-甲基呋喃-3-羧酸乙酯
  参考文献：
  名称：

  Non-nucleoside reverse transcriptase inhibitors

  摘要：

  通过式I表示的化合物：其中R2从H、(C1-4)烷基、卤素、卤代烷基、OH、(C1-6)烷氧基、NH(C1-4烷基)或N(C1-4烷基)2的组中选择；R4为H或Me；R5为H或Me；R11为H、(C1-4)烷基、(C3-4)环烷基和(C1-4)烷基-(C3-4)环烷基；A为(C1-3)烷基的连接链；B为O或S；n为0或1；其中当n为0时：环C为具有1至4个来自O、N和S的杂原子的6-或10-成员芳基或5-或6-成员杂环，所述芳基和所述杂环可选地被取代；E为CONR12R13；CONHNR14R15；NR16COR17；NR18SO2(C1-6)烷基；SO2NR19R20；或SO2R21；或当n为1时：环C如上定义，E为单键或连接基；和环D为具有1至4个来自O、N和S的杂原子的6-或10-成员芳基或5-或6-成员杂环，所述芳基和所述杂环可选地被1至5个取代基取代；或其盐或前药作为HIV逆转录酶的抑制剂。

  公开号：

  US20040006071A1

文献信息

• Novel multi-cyclic compounds and their use
  申请人：Revotar Biopharmaceuticals AG

  公开号：EP1764094A1

  公开（公告）日：2007-03-21

  Pharmaceutical compositions comprising at least one compound of the formulas (Ia) or (Ib) or (IIa) or (IIb) and a pharmaceutically acceptable carrier which is useful in a medicine wherein the symbols and substituents have the following meaning -X- is e.g. or or or and Y being or or the pharmaceutically acceptable salts, esters or amides and prodrugs of the above identified compounds of formulas (Ia) or (Ib) or (IIa) or (IIb). The compounds are applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.

  含有至少一个公式(Ia)或(Ib)或(IIa)或(IIb)中的化合物和一种药用可接受载体的制药组合物，在药物中有用，其中符号和取代基具有以下含义-X- 是例如或或或和Y 是或或上述公式(Ia)或(Ib)或(IIa)或(IIb)中识别的化合物的药用可接受盐、酯或酰胺和前药。这些化合物被应用于调节由E-、P-或L-选择素结合介导的体外和体内结合过程。
• NOVEL MULTI-CYCLIC COMPOUNDS
  申请人：Kranich Remo

  公开号：US20090030015A1

  公开（公告）日：2009-01-29

  Pharmaceutical compositions comprising at least one compound of the formulas (Ia) or (Ib) or (IIa) or (IIb) and a pharmaceutically acceptable carrier wherein the symbols and substituents have the following meaning —X— is e.g. and Y being e.g. or the pharmaceutically acceptable salts can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.

  药物组合物包括至少一种化合物，化合物的结构式为(Ia)或(Ib)或(IIa)或(IIb)，以及药学上可接受的载体。其中符号和取代基的含义如下：-X-例如，Y可以是例如，或者药学上可接受的盐，可以用于调节由E-、P-或L-选择素介导的体外和体内结合过程。
• Small Molecule Inhibitors of the Neuropilin-1 Vascular Endothelial Growth Factor A (VEGF-A) Interaction
  作者：Ashley Jarvis、Charles K. Allerston、Haiyan Jia、Birger Herzog、Acely Garza-Garcia、Natalie Winfield、Katie Ellard、Rehan Aqil、Rosemary Lynch、Chris Chapman、Basil Hartzoulakis、James Nally、Mark Stewart、Lili Cheng、Malini Menon、Michelle Tickner、Snezana Djordjevic、Paul C. Driscoll、Ian Zachary、David L. Selwood

  DOI：10.1021/jm901755g

  日期：2010.3.11

  We report the molecular design and synthesis of EG00229,2, the first small molecule ligand for the VEGF-A receptor neuropilin 1 (NRP1) and the structural characterization of NRP1-ligand complexes by NMR spectroscopy and X-ray crystallography. Mutagenesis Studies localized VEGF-A binding in the NRP1 b1 domain and it peptide Fragment of VEGF-A was shown to bind at the same site by NMR, providing the basis for small molecule design. Compound 2 demonstrated inhibition of VEGF-A binding to NRP1 and attenuated VEGFR2 phosphorylation in endothelial cells. Inhibition of migration of endothelial cells was also observed. The viability of A549 lung carcinoma cells wits reduced by 2, and it increased the potency of the cytotoxic agents paclitaxel and 5-fluorouracil when given in combination. These studies provide the basis for design of specific small molecule inhibitors of ligand binding to NRP1.
• NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP1506195B1

  公开（公告）日：2008-10-29
• NOVEL MULTI-CYCLIC COMPOUNDS AND THEIR USE
  申请人：Revotar Biopharmaceuticals AG

  公开号：EP1948146B1

  公开（公告）日：2012-11-07